314 related articles for article (PubMed ID: 23241074)
1. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
Keshtkaran A; Javanbakht M; Salavati S; Mashayekhi A; Karimi M; Nuri B
Transfusion; 2013 Aug; 53(8):1722-9. PubMed ID: 23241074
[TBL] [Abstract][Full Text] [Related]
2. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
Ho WL; Chung KP; Yang SS; Lu MY; Jou ST; Chang HH; Yang YL; Lin DT; Lin KH
J Formos Med Assoc; 2013 Apr; 112(4):221-9. PubMed ID: 23537869
[TBL] [Abstract][Full Text] [Related]
3. A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea.
Kim J; Kim Y
Value Health; 2009; 12 Suppl 3():S78-81. PubMed ID: 20586988
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
Delea TE; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Pharmacoeconomics; 2007; 25(4):329-42. PubMed ID: 17402805
[TBL] [Abstract][Full Text] [Related]
5. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
Karnon J; Tolley K; Vieira J; Chandiwana D
Clin Drug Investig; 2012 Dec; 32(12):805-15. PubMed ID: 23026844
[TBL] [Abstract][Full Text] [Related]
6. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
Luangasanatip N; Chaiyakunapruk N; Upakdee N; Wong P
Clin Drug Investig; 2011; 31(7):493-505. PubMed ID: 21627338
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
Tolley K; Oliver N; Miranda E; Migliaccio-Walle K; Bozkaya D; Li Q
J Med Econ; 2010; 13(3):559-70. PubMed ID: 20812793
[TBL] [Abstract][Full Text] [Related]
8. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
Imran F; Phatak P
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.
Karnon J; Tolley K; Oyee J; Jewitt K; Ossa D; Akehurst R
Curr Med Res Opin; 2008 Jun; 24(6):1609-21. PubMed ID: 18439348
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
[TBL] [Abstract][Full Text] [Related]
13. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
Armstrong EP; Skrepnek GH; Sasane M; Snodgrass SM; Ballas SK
J Med Econ; 2013; 16(1):10-8. PubMed ID: 22947171
[TBL] [Abstract][Full Text] [Related]
14. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
Haghpanah S; Zarei T; Zahedi Z; Karimi M
Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
16. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
17. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.
Bentley A; Gillard S; Spino M; Connelly J; Tricta F
Pharmacoeconomics; 2013 Sep; 31(9):807-22. PubMed ID: 23868464
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
McLeod C; Fleeman N; Kirkham J; Bagust A; Boland A; Chu P; Dickson R; Dundar Y; Greenhalgh J; Modell B; Olujohungbe A; Telfer P; Walley T
Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
[TBL] [Abstract][Full Text] [Related]
19. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
20. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]